Global next generation biotherapeutics market is anticipated to show a robust growth with an impressive CAGR in the forecast period, 2022-2026 on account of growing pharmaceutical industry. Moreover, evolving practices to develop advanced medicines is driving the growth of the global next generation biotherapeutics market in the upcoming five years.

Biologicals that contain an active substance derived from natural and biological sources are termed as biotherapeutics. These biotherapeutics are actively utilized for the treatment of various diseases and disorders. Next generation biotherapeutics are advanced versions in the already available therapeutics in the market that although act on the same target cell/ tissue/ organ but possess added properties due to antibody conjugation, radiolabeling, PEGylation and glycol-conjugation.

Advancing Biotechnology Sector Drives Market Growth

Consistent demand for advanced medicines is anticipated to drive the growth of the global next generation biotherapeutics market in the upcoming five years. Processes like gene therapy, monoclonal Antibody (mAb), gene silencing, DNA & RNA editing technologies, and stem cell therapy are aiding the growth of the global next generation biotherapeutics market in the next five years. Many biopharmaceutical companies are moving on from traditional monoclonal antibody therapies to exploiting intricate antibody structures and new genetic medicines.

Increasing Clinical Trials Support Market Growth

The US Food and Drug Administration (FDA) is accountable for the authorization of any drugs to be used and commercialized for the general public. The process of manufacturing and finalizing a drug to be used for the treatment of a particular symptom or disease is done after multiple levels of clinical trials. Any drug that has been produced must undergo a series of inspection and research. The research should study the chemical, physical, emotional, and other effects of that particular drug on animals, humans, diseased, and non-diseased, meanwhile maintaining the integrity of the experiments as well as the test subjects at risk. The increasing clinical trials, and the FDA approvals for the pharmaceuticals are expected to contribute to the growth of the global next generation biotherapeutics market in the next five years.

However, delayed FDA approvals might challenge the future growth of market. For the approval of utilization, and commercialization of the drug, the manufacturer must undergo an intense series of experimentation, clinical trials, and ethical boundaries, that requires investments including financial aids.

Increasing Instances of Chronic Diseases

The world has recently overcame the impact of COVID-19 pandemic. Although the infectious disease and its infection has not yet completely irradicated. The conditions of the pandemic have been taken under control to a larger extent. The sudden outbreak of the viral infection upsurged the demand for increasing the extensive and definitive research and technological advancements such that the diseases and their outbreak can be handled in better and efficient way.

COVID-19 also ensured the rising demand for early diagnosis of the diseases. The increasing concerns for the early diagnosis of the diseases and disorders is aiding the growth of the global next generation biotherapeutics market. With early diagnosis, efficient and effective treatment demand is also experienced, and thus extended research for the pharmaceutical products that can help the fast and effective recovery of the patient, is also increasing, thereby driving the growth of the global next generation biotherapeutics market in the future five years. Also, increasing instances of chronic diseases like cancer, neurological disorders, and genetic diseases are further supporting the growth of the global next generation biotherapeutics market in the upcoming five years.

Increasing Application of Biotherapeutics to Drive Market Growth

Increasing application of next generation biotherapeutics is also anticipated to substantiate the growth of the global next generation biotherapeutics market in the upcoming five years The wide arena of applications of next generation biotherapeutics include understanding the potential adverse reactions of monoclinal antibodies (mAb) gene therapy, cancer therapy, vaccines, gene silencing, DNA gene editing technologies, RNA palindromic repeat manipulation techniques, protein engineering, stem-cell therapy, etc.


Click here to download the sample

Market Segmentation

The global next generation biotherapeutics market is segmented on the basis of therapeutic area, technology, competitional landscape, and regional distribution. Based on therapeutic area, the market is further fragmented into oncology, autoimmune/ inflammatory diseases. On the basis of technology, the market is segmented into antibody-drug conjugates, bispecific antibodies, antibody fragments, antibody-like proteins, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profiles

Xencor, Inc., Regenxbio & Neurimmune AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., AstraZeneca Plc., F. Hoffmann-La Roche AG, Kyowa Kirin Co., Ltd, Seattle Genetics, Inc, ImmunoGen, Inc, Ono Pharmaceuticals Co, Ltd, are among the major market players in the global platform that lead the market growth of the global next generation biotherapeutics market.

Attribute

Details

Base Year

2020

Historical Years

2016 – 2019

Estimated Year

2021

Forecast Period

2022 – 2026

Quantitative Units

Revenue in USD Million, and CAGR for 2016-2020 and 2021-2026

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

  • Therapeutic Area
  • Technology

Regional Scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country Scope

United States; Mexico; Canada; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Saudi Arabia; UAE; South Africa; Kuwait; Brazil; Argentina; Colombia

Key Companies Profiled

Xencor, Inc., Regenxbio & Neurimmune AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., AstraZeneca Plc., F. Hoffmann-La Roche AG, Kyowa Kirin Co., Ltd, Seattle Genetics, Inc, ImmunoGen, Inc, Ono Pharmaceuticals Co, Ltd

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global next generation biotherapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Next Generation Biotherapeutics Market, By Therapeutic Area:
    • Oncology
    • Autoimmune/ Inflammatory Diseases
  • Next Generation Biotherapeutics Market, By Technology:
    • Antibody-Drug Conjugates
    • Bispecific Antibodies
    • Antibody Fragments
    • Antibody-like Proteins
    • Others
  • Next Generation Biotherapeutics Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Kuwait
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global next generation biotherapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Next Generation Biotherapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Next Generation Biotherapeutics Market

4.    Voice of Customer

4.1.  Brand Awareness

4.2.  Factors Contributing to Switch over to Next Generation Biotherapeutics

4.3.  Barriers to Adoption of Next Generation Biotherapeutics

5.    Executive Summary

6.    Global Next Generation Biotherapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapeutic Area (Oncology, Autoimmune/Inflammatory Diseases)

6.2.2.     By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others)

6.2.3.     By Company (2020)

6.2.4.     By Region

6.3.  Product Market Map

7.    North America Next Generation Biotherapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapeutic Area

7.2.2.     By Technology

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Next Generation Biotherapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapeutic Area

7.3.1.2.2.             By Technology

7.3.2.     Mexico Next Generation Biotherapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapeutic Area

7.3.2.2.2.             By Technology

7.3.3.     Canada Next Generation Biotherapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapeutic Area

7.3.3.2.2.             By Technology

8.    Europe Next Generation Biotherapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapeutic Area

8.2.2.     By Technology

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Next Generation Biotherapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapeutic Area

8.3.1.2.2.             By Technology

8.3.2.     Germany Next Generation Biotherapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapeutic Area

8.3.2.2.2.             By Technology

8.3.3.     United Kingdom Next Generation Biotherapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapeutic Area

8.3.3.2.2.             By Technology

8.3.4.     Italy Next Generation Biotherapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapeutic Area

8.3.4.2.2.             By Technology

8.3.5.     Spain Next Generation Biotherapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapeutic Area

8.3.5.2.2.             By Technology

9.    Asia-Pacific Next Generation Biotherapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapeutic Area

9.2.2.     By Technology

9.2.3.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Next Generation Biotherapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapeutic Area

9.3.1.2.2.             By Technology

9.3.2.     India Next Generation Biotherapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapeutic Area

9.3.2.2.2.             By Technology

9.3.3.     South Korea Next Generation Biotherapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapeutic Area

9.3.3.2.2.             By Technology

9.3.4.     Japan Next Generation Biotherapeutics Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Therapeutic Area

9.3.4.2.2.             By Technology

9.3.5.     Australia Next Generation Biotherapeutics Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Therapeutic Area

9.3.5.2.2.             By Technology

10.  South America Next Generation Biotherapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapeutic Area

10.2.2.  By Technology

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Next Generation Biotherapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapeutic Area

10.3.1.2.2.           By Technology

10.3.2.  Argentina Next Generation Biotherapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapeutic Area

10.3.2.2.2.           By Technology

10.3.3.  Colombia Next Generation Biotherapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapeutic Area

10.3.3.2.2.           By Technology

11.  Middle East and Africa Next Generation Biotherapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapeutic Area

11.2.2.  By Technology

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Next Generation Biotherapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapeutic Area

11.3.1.2.2.           By Technology

11.3.2.  Saudi Arabia Next Generation Biotherapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapeutic Area

11.3.2.2.2.           By Technology

11.3.3.  UAE Next Generation Biotherapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapeutic Area

11.3.3.2.2.           By Technology

11.3.4.  Kuwait Next Generation Biotherapeutics Market Outlook

11.3.4.1.      Market Size & Forecast

11.3.4.1.1.           By Value

11.3.4.2.      Market Share & Forecast

11.3.4.2.1.           By Therapeutic Area

11.3.4.2.2.           By Technology

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1. Xencor, Inc.

14.2. Regenxbio & Neurimmune AG

14.3. Takeda Pharmaceutical Company Limited

14.4. Pfizer, Inc.

14.5. AstraZeneca Plc.

14.6. F. Hoffmann-La Roche AG

14.7. Kyowa Kirin Co., Ltd

14.8. Seattle Genetics, Inc

14.9. ImmunoGen, Inc

14.10. Ono Pharmaceuticals Co, Ltd

15.  Strategic Recommendations

16.  About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com